CN106265654A - Adjudin application in preparing slow down aging medicine - Google Patents
Adjudin application in preparing slow down aging medicine Download PDFInfo
- Publication number
- CN106265654A CN106265654A CN201610664074.4A CN201610664074A CN106265654A CN 106265654 A CN106265654 A CN 106265654A CN 201610664074 A CN201610664074 A CN 201610664074A CN 106265654 A CN106265654 A CN 106265654A
- Authority
- CN
- China
- Prior art keywords
- slow down
- adjudin
- medicine
- down aging
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to field of medicine preparation, particularly to Adjudin application in preparing slow down aging medicine, described slow down aging medicine is at least one dosage form in tablet, capsule, granule, drop pill, suspensoid, syrup, enteric coated preparation, Emulsion suspension and injection.The invention provides Adjudin application in preparing slow down aging medicine, experiment shows, Adjudin can promote the survival of senile cell, significantly reduce the beta galactosidase that intracellular aging is relevant, significantly improve the situation of cell cycle arrest, show that Adjudin has important using value in preparing slow down aging medicine.The present invention provides experimental data for the most more reasonably being applied by Adjudin in slow down aging medicine.
Description
Technical field
The invention belongs to field of medicine preparation, particularly to Adjudin application in preparing slow down aging medicine.
Background technology
Cell ageing refers to that normal diploid cell stops division, is that telomere shortens, the final knot causing DNA damage reaction
Really.Additionally, active oxygen (ROS) is assembled, oncogene activation, the activation that cell merges all can cause DNA damage, thus cause cell
Old and feeble.Cell ageing is the change of cell state.For cell aspect, old and feeble relevant beta galactosidase becomes the positive, dye
Chromaticness form changes.
Adjudin, has another name called AF-2364, and in prior art, Adjudin is to be found as male contraceptive pill, is chemotherapeutic
The derivant of lonidamine (lonidamine), is the class small-molecule drug with indolic acid structure.The chemical machine of Adjudin
Structure formula is:
In prior art, not having research to confirm, Adjudin can apply as the medicine of slow down aging.
Summary of the invention
It is an object of the invention to provide Adjudin application in slow down aging medicine, senile cell can be effectively improved and deposit
Motility rate, reduces the relevant beta galactosidase of aging and expresses, improve cell cycle arrest.
Described slow down aging medicine is tablet, capsule, granule, drop pill, suspensoid, syrup, enteric coated preparation, breast
At least one dosage form in agent suspension and injection.
Described slow down aging medicine is the medicine of suppression cell beta galactosidase.
Described slow down aging medicine is the medicine improving cell cycle arrest.
Described slow down aging medicine is the medicine improving ability of cell proliferation.
Above-mentioned cell is fibroblast.
The invention have the benefit that
1, the invention provides Adjudin application in preparing slow down aging medicine, experiment shows, Adjudin is permissible
Promote the survival of senile cell, significantly reduce the beta galactosidase that intracellular aging is relevant, significantly improve cell cycle arrest
Situation, show that Adjudin has important using value in preparing slow down aging medicine.
2, the present invention provides experimental data for the most more reasonably being applied by Adjudin in slow down aging medicine.
Accompanying drawing explanation
Fig. 1 is in embodiment 1, and Adjudin promotes senile cell survival rate comparison diagram.
Fig. 2 is in embodiment 1, and Adjudin reduces the expression comparison diagram of the relevant beta galactosidase of intracellular aging.
Fig. 3 is in embodiment 1, the protein content comparison diagram that after Adjudin process, cell cycle is relevant.
Detailed description of the invention
Below in conjunction with embodiment, the invention will be further described:
Embodiment 1
1, cell is cultivated and induction aging:
Cell used by the present embodiment is mouse embryo fibroblasts (MEF).Take pregnant Mus, separate tire Corium Mus skin, it is thus achieved that
MEF.With hydroxyurea (HU) Induction of Cellular senescence, build senile cell model.
2, cell survival experiment
Being spread by MEF in 96 orifice plates and cultivate, the Adjudin that concentration is respectively 0,5,10,20,40,80 μm ol/L locates in advance
Add hydroxyurea (HU) the induction aging of 6mmol/L after managing 1 hour, add CCK-8 reagent after 24 hours, hatch 1.5 little
Using microplate reader reading time after, and matched group is not added with HU, its concrete outcome as it is shown in figure 1, it is seen that Adjudin not
Meeting cell growth inhibiting, and under the stimulation of HU, can promote to be induced the survival of senile cell, especially concentration is 20-40 μ
Mol/L, its facilitation is particularly evident.
3, the beta galactosidase experiment that intracellular aging is relevant
Being spread by MEF in 6 orifice plates and cultivate, the Adjudin pretreatment 1 that concentration is respectively 0,10,20,40 μm ol/L is little
Time, add 6mmol/L hydroxyurea (HU) induction aging, by cell dyeing after 24 hours, and matched group is not added with HU.Agents useful for same
For green skies cell ageing beta galactosidase staining kit, dye according to description appended by test kit, use afterwards
Inverted microscope light field shoots, and counting processes.Found that: with the relevant β-gala of the intracellular aging that HU induction is old and feeble
Glycosidase significantly rises, and senile cell digital display writes and increases, and this phenomenon can be by 10 μm ol/L, 20 μm ol/L, 40 μm ol/L
Adjudin substantially alleviates, and illustrates that Adjudin can significantly reduce the beta galactosidase that intracellular aging is relevant, concrete such as Fig. 2 institute
Show.
4, cell cycle experiment
Cell is spread in 6 orifice plates and cultivate, the Adjudin pretreatment that concentration is 40 μm ol/L is added for 1 hour afterwards
6mmol/L hydroxyurea (HU) induction aging, received albumen after 24 hours.SDS-PAGE is i.e. used by the method for Western Blot
Run glue, then albumen is forwarded on the nitrocellulose membrane of 0.45 μm pore size, use a corresponding anti-overnight incubation, within second day, hatch
Two anti-after the relevant Protein p16 of the method detection cell cycle of development, p21 expression in cell.Experiment finds, hydroxyurea
The cell p16, p21 of induction aging significantly raise at protein expression, and this phenomenon can be shown by 40 μm ol/L Adjudin
Write and reduce.Result is as shown in Figure 3.
Showing according to result above, Adjudin (AF-2364) can be with slow down aging: be effectively improved senile cell survival, fall
The beta galactosidase that low aging is relevant is expressed, and improves cell cycle arrest.Show that Adjudin is in preparing slow down aging medicine
There is significant application value.
All data in above-mentioned experiment are given according to the mode of mean+SD.Data use single factor test variance to divide
Analysis is estimated, and then uses Student-Newman-Keuls post hoc test.P value is considered statistics less than 0.05
Significantly.
The above is presently preferred embodiments of the present invention, but the present invention should not be limited to disclosed in this embodiment
Content.So every without departing from the equivalence completed under spirit disclosed in this invention or amendment, both fall within the model of present invention protection
Enclose.
Claims (6)
1.Adjudin application in preparing slow down aging medicine.
Application the most according to claim 1, it is characterised in that: described slow down aging medicine is tablet, capsule, granule
At least one dosage form in agent, drop pill, suspensoid, syrup, enteric coated preparation, Emulsion suspension and injection.
Application the most according to claim 1, it is characterised in that: described slow down aging medicine is suppression cell beta galactose glycosides
The medicine of enzyme.
Application the most according to claim 1, it is characterised in that: described slow down aging medicine is to improve cell cycle arrest
Medicine.
Application the most according to claim 1, it is characterised in that: described slow down aging medicine is to improve ability of cell proliferation
Medicine.
6. according to the application according to any one of claim 3-5, it is characterised in that: described cell is fibroblast.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610664074.4A CN106265654A (en) | 2016-08-12 | 2016-08-12 | Adjudin application in preparing slow down aging medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610664074.4A CN106265654A (en) | 2016-08-12 | 2016-08-12 | Adjudin application in preparing slow down aging medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106265654A true CN106265654A (en) | 2017-01-04 |
Family
ID=57670191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610664074.4A Pending CN106265654A (en) | 2016-08-12 | 2016-08-12 | Adjudin application in preparing slow down aging medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106265654A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024041604A1 (en) * | 2022-08-24 | 2024-02-29 | 四川大学华西第二医院 | Use of yogurt-derived polypeptide in preparation of drug for delaying telomere shortening and anti-aging drug |
-
2016
- 2016-08-12 CN CN201610664074.4A patent/CN106265654A/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| XIA WL等: "A sirtuin activator and an anti-inflammatory molecule-multifaceted roles of adjudin and its potential applications for aging-related diseases", 《SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024041604A1 (en) * | 2022-08-24 | 2024-02-29 | 四川大学华西第二医院 | Use of yogurt-derived polypeptide in preparation of drug for delaying telomere shortening and anti-aging drug |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wagner | Cell types and connectivity patterns in mosaic retinas | |
| Princz et al. | The role of SUMOylation in ageing and senescent decline | |
| Martínez‐Zaguilán et al. | Distinct regulation of pHin and [Ca2+] in in human melanoma cells with different metastatic potential | |
| Snow et al. | Calcium buffer injections delay cleavage in Xenopus laevis blastomeres | |
| CN106265654A (en) | Adjudin application in preparing slow down aging medicine | |
| Byers et al. | Colonic short‐chain fatty acids inhibit encystation of Entamoeba invadens | |
| Lee et al. | Matairesinol inhibits angiogenesis via suppression of mitochondrial reactive oxygen species | |
| Yan et al. | Anti-glycated and antiradical activities in vitro of polysaccharides from Ganoderma capense | |
| CN102952756A (en) | Marine fungi altemaria MNP801 and application thereof | |
| Vogt et al. | Causes and consequences of stolon regression in a colonial hydroid | |
| Zhou et al. | Seed coat morphology in Sapium sebiferum in relation to its mechanism of water uptake | |
| CN111494231B (en) | Application of three natural components in licorice root as tyrosinase inhibitor and whitening | |
| Naumann et al. | FoxN3 is necessary for the development of the interatrial septum, the ventricular trabeculae and the muscles at the head/trunk interface in the African clawed frog, Xenopus laevis (Lissamphibia: Anura: Pipidae) | |
| CN106974907A (en) | A kind of application of 4 aryl-coumarin class compound | |
| CN106176713A (en) | The new application of α-Garcinia mangostana flavone | |
| CN105166917A (en) | Lemon ferment nutrition solution and preparation method thereof | |
| Bishop | State Capacity and International Politics | |
| Dobbeler | Hyperepiphyllous, perianthicolous Hypocreales—highly specialized ascomycetes of the phyllosphere | |
| CN104800849B (en) | A kind of application of inhibitors of phosphatidylinositol3 3-kinase | |
| CN109966284B (en) | Application of chaetomium globosum lour in preparation of antifungal drug sensitizer | |
| TWI726730B (en) | A method for treatment of cellular senescence | |
| CN108164529A (en) | A kind of micromolecular inhibitor SLD9059 and its application in pharmacy | |
| CN103751210A (en) | Application of extracting solution of natural multi-form arsenic | |
| Hoover et al. | The silver mint of Damascus under Demetrius III and Antiochus XII (97/6 BC-83/2 BC) | |
| CN108186641B (en) | Application of GSK2193874 in preparing anti-glioma medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170104 |